InMode (INMD) Cash from Investing Activities (2018 - 2026)
InMode (INMD) posted quarterly Cash from Investing Activities of $109.1 million for Q1 2026, up 44.54% year-on-year from $75.5 million in Q1 2025, and up 300.78% on a QoQ basis from $27.2 million in Q4 2025.
InMode (INMD) Cash from Investing Activities (2018 - 2026) Analysis & Trends
InMode (INMD) has reported Cash from Investing Activities for 9 consecutive years, with $109.1 million the latest figure, recorded in Q1 2026.
- Quarterly Cash from Investing Activities rose 44.54% year-over-year to $109.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $219.6 million (down 22.95% YoY) and the FY2025 annual result came in at $186.0 million, up 14.69% from the prior year.
- Cash from Investing Activities rose to $109.1 million in Q1 2026 per INMD's latest filing, from $27.2 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for INMD reached as high as $114.1 million in Q3 2024 and fell as low as -$69.8 million in Q3 2023.
- A 5-year average of $12.5 million and a median of $11.7 million in 2025 frame the typical range for Cash from Investing Activities.
- The largest YoY upside for Cash from Investing Activities was 647.89% in 2023 against a maximum downside of 117.11% in 2023.
- Year by year, Cash from Investing Activities stood at -$38.3 million in 2022, then plunged by 34.79% to -$51.6 million in 2023, then jumped by 250.84% to $77.8 million in 2024, then sank by 65.02% to $27.2 million in 2025, then jumped by 300.78% to $109.1 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $109.1 million, $27.2 million, and $11.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | InMode | 981,130.50 | -479.15 Mn | 61.55 Mn | 109.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109.10 Mn |
| Mar 31, 2026 | 109.10 Mn |
| Dec 31, 2025 | 27.22 Mn |
| Dec 31, 2025 | 27.22 Mn |
| Sep 30, 2025 | 11.67 Mn |
| Sep 30, 2025 | 11.67 Mn |
| Jun 30, 2025 | 71.66 Mn |
| Jun 30, 2025 | 71.66 Mn |
| Mar 31, 2025 | 75.49 Mn |
| Mar 31, 2025 | 75.49 Mn |
| Dec 31, 2024 | 77.82 Mn |
| Dec 31, 2024 | 77.82 Mn |
| Sep 30, 2024 | 114.06 Mn |
| Sep 30, 2024 | 114.06 Mn |
| Jun 30, 2024 | 17.73 Mn |
| Jun 30, 2024 | 17.73 Mn |
| Mar 31, 2024 | -47.39 Mn |
| Mar 31, 2024 | -47.39 Mn |
| Dec 31, 2023 | -51.59 Mn |
| Dec 31, 2023 | -51.59 Mn |